Add BrightSurf on Google Email

Boston Children's Hospital


Your baby's brain on drugs (and alcohol and tobacco)

A study using MRI scans found that prenatal exposure to these substances can reduce cortical gray matter and total brain volumes. The effects were additive, with more substances leading to greater reductions in brain volume. Health care providers should offer comprehensive care to pregnant women to help reduce psychoactive substance use.

SourceBoston Children's Hospital·JournalPEDIATRICS·DateApr 7, 2008

Anemia treatment may be a double-edged sword

A mouse study reveals that erythropoietin keeps blood vessels alive and growing in the eye, but administering it at the wrong time may worsen diseases. The hormone's effects depend on timing, with early administration potentially slowing disease progression and late administration accelerating it.

SourceBoston Children's Hospital·JournalJournal of Clinical Investigation·DateJan 30, 2008

An 'attractive' man-machine interface

Scientists at Boston Children's Hospital have created a new technology that uses magnetic fields to control cellular signaling, mimicking the binding of drugs or hormones. This innovation has the potential to lead to finely-tuned but noninvasive treatments for various diseases.

SourceBoston Children's Hospital·JournalNature Nanotechnology·DateJan 8, 2008

Why are African American women more likely than whites to die from breast cancer?

Researchers found that African American women are diagnosed with breast cancer at an average age of 46, compared to 57 for white women. The study proposes that the excess mortality occurs partly because black women are more likely to develop breast cancer before menopause, when surgery may pose a higher risk of stimulating cancer growth.

SourceBoston Children's Hospital·JournalInternational Journal of Surgery·DateFeb 21, 2007

New forecasting tool could reduce drug development costs

Researchers developed a Bayesian network model to forecast the success of new drugs, reducing mean capitalized expenditures by an average of $283 million per successful new drug. More data sharing by the pharmaceutical industry could improve forecasting accuracy and benefit patients by eliminating unsafe investigational new drugs.

SourceBoston Children's Hospital·JournalNature Reviews Drug Discovery·DateFeb 1, 2007

Getting to the heart of the heart

A type of stem cell has been identified that gives rise to both myocardial cells and vascular smooth muscle cells, challenging previous notions of how the heart develops. This discovery could lead to the development of new treatments for congenital heart defects and damage caused by heart attacks.

Rescuing injured hearts by enhancing regeneration

Researchers at Boston Children's Hospital developed a two-drug treatment that rescues heart function after a heart attack by promoting blood vessel growth and cell division. The study shows improved heart function and reduced scarring in rats treated with the combination of agents.

SourceBoston Children's Hospital·JournalProceedings of the National Academy of Sciences·DateOct 9, 2006

The right kind of oil

Researchers have discovered that substituting Omegaven, an IV fat mixture made from fish oil, can prevent fat accumulation and liver injury in patients with parenteral nutrition. The study has shown promising results in treating liver disease in children and adults, with most patients experiencing complete resolution of the condition.

SourceBoston Children's Hospital·JournalPEDIATRICS·DateJul 3, 2006

Boosting newborns' immune responses

A study published in Blood found that the newborn immune system functions differently than adults, but one portion of the response is fully functional and can be harnessed to improve immunity. The researchers identified a specific Toll-like receptor, TLR8, that triggers a robust immune response in newborns.

SourceBoston Children's Hospital·JournalBlood·DateApr 25, 2006

A new view of asthma's cause

A recent study published in PNAS found that at least two-thirds of asthma patients' pulmonary T cells are actually NKT cells, not conventional Th2 cells. This discovery may lead to the development of new treatments targeting NKT cells.

SourceBoston Children's Hospital·JournalNew England Journal of Medicine·DateMar 15, 2006